This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • LP0058-1005 - A Open-Label, Four-Way Crossover and...
Clinical trial

LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects

Read time: 1 mins
Last updated:7th Apr 2014

LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor"), with an aim to help people with skin conditions called psoriasis. The aim (s) of this Study are to determine:

- The effects of the Study Drug when given as different formulations intended for oral administration (tablets and capsules)
- The safety of the Study Drug and any side effects that might be associated with it
- The effect of food on the Study Drug
- The Study will also measure how much of the Study Drug gets into the blood stream and how long it takes the body to remove it and what affect the Study Drug has on the body.

Category Value
Study start date 2014-04-07

View full details